BXRX Projected Dividend Yield

Com Par $0.01/Baudax Bio Inc ( OTCBB : BXRX )

Baudax Bio is a pharmaceutical company primarily focused on commercializing and developing products for hospital and related acute care settings. Co. has launched its commercial product, ANJESO in the U.S. ANJESO is an intravenous analgesic agent. ANJESO is a cyclooxygenase-2 preferential, non-steroidal anti-inflammatory, or NSAID for the management of moderate to severe pain, which can be administered alone or in combination with other non-NSAID analgesics. Co.'s pipeline also includes other earlier stage product candidates including intermediate and short-acting neuromuscular blocking agents, and accompanying reversal agents that Co. is developing for use in hospital or related settings.

13 YEAR PERFORMANCE RESULTS